Intec Pharma (NSDQ:NTEC) said today that it inked a deal with the Michael J. Fox Foundation for Parkinson’s Research to support the biopharmaceutical company’s patient recruitment and retention for its pivotal phase III trial. The study will evaluate Intec Pharma’s lead candidate, the “accordion pill” carbidopa/levodopa (AP-CD/LD), as a treatment for patients with advanced Parkinson’s disease. The Israel-based company began enrolling patients in its phase III trial in April 2016.
In 2013, the Michael J. Fox foundation supported the company with a $705,000 grant to fund a preclinical evaluation of its oral drug delivery system in Parkinson’s disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Intec Pharma inks deal with Michael J. Fox Foundation for patient recruitment appeared first on MassDevice.